It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...
The need for cell therapy production improvements is acute, which in turn lends support to approaches like Cellares’ and Ori’s, Tracxn said in its report ...
To qualify for advanced manufacturing technology designation from the FDA, a company must present a manufacturing approach that incorporates a new technology or uses an established technology in a ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
Cell and gene therapy manufacturing relies on complex cell processing, viral vector production, quality control, and GMP-compliant workflows to consistently produce safe and effective therapies at ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results